Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Richard, M. P.
Right arrow Articles by Marre, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richard, M. P.
Right arrow Articles by Marre, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 41, 207-214, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

REVIEWS

Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance

MP Richard, AG Aguado, R Mattina and R Marre
Rhone DPC, Antony, France.

A survey of resistance to sparfloxacin was carried out in ten European countries, namely Slovakia, France, Germany, Great Britain, Hungary, the Republic of Ireland, Italy, The Netherlands, Portugal and Spain. Respiratory samples were collected from 4297 patients with lower respiratory tract infections and cultured for the presence of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Altogether 2101 strains were isolated and tested for their susceptibility to sparfloxacin, ciprofloxacin, erythromycin, tetracycline and penicillin G (S. pneumoniae) or amoxycillin (H. influenzae and M. catarrhalis). Each country tested strains using methods commonly used in that country, and with breakpoints selected based on those used in that country. Penicillin resistance in pneumococci was seen in those countries in which it had been reported previously, namely Spain, France and Hungary. Only four strains of pneumococci were resistant to sparfloxacin (MIC > or = 2 mg/L), while ciprofloxacin-resistant strains were isolated more frequently, particularly in the Republic of Ireland and Hungary. Almost all of the strains of H. influenzae tested were resistant to erythromycin, (MIC50 > or = 4 mg/L), but all strains were highly sensitive to sparfloxacin (MIC90 < or = 0.06 mg/L). The number of strains of H. influenzae producing beta-lactamase varied between countries, whereas most strains of M. catarrhalis produced beta-lactamase. In M. catarrhalis, erythromycin and tetracycline resistance was rare, but sensitivity to amoxycillin varied. Sparfloxacin was particularly active against H. influenzae and M. catarrhalis, and was the most active compound tested. Overall, the activity of sparfloxacin was greater than that of ciprofloxacin against all three pathogens, and resistance to it was rare.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. E. Jones, J. A. Karlowsky, R. Blosser-Middleton, I. Critchley, C. Thornsberry, and D. F. Sahm
Relationship between Antibiotic Resistance in Streptococcus pneumoniae and That in Haemophilus influenzae: Evidence for Common Selective Pressure
Antimicrob. Agents Chemother., September 1, 2002; 46(9): 3106 - 3107.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. Piroth, N. Desbiolles, V. Mateo-Ponce, L. Martin, C. Lequeu, P.-E. Charles, H. Portier, and P. Chavanet
HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae
J. Antimicrob. Chemother., January 1, 2001; 47(1): 33 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. E. Jones, A. M. Staples, I. Critchley, C. Thornsberry, P. Heinze, H. D. Engler, and D. F. Sahm
Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States
Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2645 - 2652.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
D. F. Sahm, M. E. Jones, M. L. Hickey, D. R. Diakun, S. V. Mani, and C. Thornsberry
Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
J. Antimicrob. Chemother., April 1, 2000; 45(4): 457 - 466.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. K. Chen, A. McGeer, J. C. de Azavedo, D. E. Low, and The Canadian Bacterial Surveillance Network
Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
N. Engl. J. Med., July 22, 1999; 341(4): 233 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. L. Butler, C. J. Jakielaszek, L. A. Miller, and J. A. Poupard
Escherichia coli ATCC 35218 as a Quality Control Isolate for Susceptibility Testing of Haemophilus influenzae with Haemophilus Test Medium
Antimicrob. Agents Chemother., February 1, 1999; 43(2): 283 - 286.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.